Certara, INC

Certara, Inc. clarifies a misstatement regarding the 2025 adjusted EBITDA of its divested Regulatory and Medical Writing business, confirming no impact on prior financial results or future outlook.

Certara announced its second quarter 2026 financial results, reporting modest revenue growth, a net loss, and a decrease in Adjusted EBITDA, while reaffirming its full-year revenue guidance and authorizing an additional $50 million share repurchase program.

Certara, Inc. reports the departure of its President and Chief Commercial Officer, Leif E. Pedersen, effective August 1, 2026, with a transition plan in place.

Certara announced its first quarter 2026 financial results, reporting a 1% revenue increase and a net loss, while also completing the divestiture of its medical writing business.

Certara, Inc. has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, aiming to sharpen its focus on Model-Informed Drug Development (MIDD).

Cynthia Collins will resign from Certara's Board of Directors and Audit Committee, effective May 14, 2026, citing no disagreements with the company.

Certara, Inc. announced its Q2 2026 financial results, reporting a net loss from continuing operations and completing the sale of its medical writing business.

Certara, Inc. reported Q1 2026 results with a net loss, while also announcing the divestiture of its global medical writing business.

Certara, Inc. reported a 10% increase in total revenues for Q3 2025, reaching $104.6 million, and a significant rebound to net income of $1.5 million from a net loss in the prior year.

Certara, Inc. reported significant revenue increases and a return to net income for the first half of 2025, driven by robust demand and strategic acquisitions.

Certara's Q1 2025 shows a 10% revenue increase, fueled by strong performance in both its software and technology-enabled services segments.

Certara, Inc. announced its financial results for the third quarter of 2024, showing an 11% increase in total revenue compared to the same period last year.

Certara, Inc. announced a 9% increase in total revenues to $418.8 million and significantly reduced its net loss to $1.6 million for the fiscal year ended December 31, 2025, driven by strong demand and strategic acquisitions.

Certara's 2024 annual report highlights its position as a leader in biosimulation, focusing on growth strategies, financial performance, and strategic considerations including a review of its regulatory services business.

Certara, Inc. has filed an amendment to its 2023 annual report to explicitly state management's conclusion that its internal controls over financial reporting were effective as of December 31, 2023.

Certara Inc. released its annual 10-K filing, detailing its position as a leading provider of biosimulation technology and solutions for the biopharmaceutical industry.

Rona Anhalt, Chief Human Resources Officer at Certara, Inc., reported transactions involving restricted stock units and common stock.

Certara, Inc. SVP and General Counsel Daniel Corcoran reported transactions involving restricted stock units and common stock.

Certara, Inc. director Cynthia Collins acquired 15,757 shares of common stock following the vesting of restricted stock units.

Certara CFO John V.W. Reynders acquired 15,757 shares through RSU vesting and was granted 33,222 new restricted stock units.

Certara, Inc. director Arjun Bedi reported the vesting of restricted stock units and a new grant of equity as part of annual compensation.

Director Nancy Killefer acquired 15,757 shares of Certara, Inc. common stock through the vesting of restricted stock units.

Certara, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 14, 2026, and highlighted a leadership transition with Jon Resnick succeeding William Feehery as CEO.

Certara, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on May 21, 2025, with proxy materials available online.

Certara will hold its 2025 Annual Meeting of Stockholders virtually on May 21, 2025, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Certara Inc. has issued a supplement to its definitive proxy statement to correct an error regarding the treatment of abstentions and broker non-votes on Proposals 2A and 2B and to incorporate additional clarifying changes.

Certara, Inc. announces its 2024 Annual Meeting of Shareholders, featuring proposals including director elections, amendments to the Certificate of Incorporation, ratification of the accounting firm, and an advisory vote on executive compensation.

Certara, Inc. will hold its annual stockholders meeting virtually on May 21, 2024, to vote on director elections, amendments to the Certificate of Incorporation, ratification of the accounting firm, and executive compensation.

Arsenal Capital Partners has filed an amendment to its Schedule 13D, extending the lock-up period for a significant portion of its Certara, Inc. common stock until April 14, 2026.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 3.9% of Certara Inc.'s common stock as of June 30, 2026.

Wasatch Advisors LP has reported a beneficial ownership of 5,272,166 shares, representing 3.3% of the class, in Certara Inc. as of March 31, 2026.

Wasatch Advisors LP has reported a beneficial ownership of 5,272,166 shares, representing 3.3% of the class, in Certara Inc. as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Certara Inc. following an internal realignment, with subsidiaries now reporting separately.

Deerfield Management entities and James E. Flynn have reported a beneficial ownership of 4.90% in Certara, Inc., falling below the 5% threshold.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn collectively report beneficial ownership of 6.29% of Certara, Inc.'s common stock.